Throughout the COVID-19 pandemic, the biopharma industry has faced numerous challenges. From drug supply shortages to lack of biomanufacturing capacity, a multitude of factors have affected and continue to affect populations worldwide. Improving the global biomanufacturing supply chain remains a top priority, as lessons learned from the pandemic continue to emerge. One of the weakest areas for improvement in the industry is access to talent. A skills gap is capable of slowing production and even making manufacturing errors. Learn how the combination of advanced digital learning technology and professional training and education programs is key for training local talent and securing biomanufacturing resilience.